KR890006254A - 비-특이적 면역성 인듀서의 제조방법 - Google Patents

비-특이적 면역성 인듀서의 제조방법 Download PDF

Info

Publication number
KR890006254A
KR890006254A KR1019880013396A KR880013396A KR890006254A KR 890006254 A KR890006254 A KR 890006254A KR 1019880013396 A KR1019880013396 A KR 1019880013396A KR 880013396 A KR880013396 A KR 880013396A KR 890006254 A KR890006254 A KR 890006254A
Authority
KR
South Korea
Prior art keywords
virus
specific immune
making non
harvest
minutes
Prior art date
Application number
KR1019880013396A
Other languages
English (en)
Other versions
KR0130775B1 (ko
Inventor
마이어 안톤
타인 페터
스트루베 발터
Original Assignee
루디 마이어, 권터 슈마허
바이엘 아크티엘젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 루디 마이어, 권터 슈마허, 바이엘 아크티엘젤샤프트 filed Critical 루디 마이어, 권터 슈마허
Publication of KR890006254A publication Critical patent/KR890006254A/ko
Application granted granted Critical
Publication of KR0130775B1 publication Critical patent/KR0130775B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24261—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

내용 없음

Description

비-특이적 면역성 인듀서의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 비-특이적 면역성 인듀서의 제조에 사용되는 바이러스 현탁액을 불활성화시키는 방법에 있어서, 바이러스 스득물을 pH 증가 및 가열의 두 단계로 불활성화 시킴을 특징으로 하는 방법.
  2. 제1항에 있어서, 사용되는 바이러스 수득물이 오르프바이러스(orfvirus)종의 파라폭스바이러스(parapoxvirus) 또는 구진성구내염 바이러스(stomatitis papulosa virus)임을 특징으로 하는 방법.
  3. 제1항에 있어서, 바이러스 수득물을 처음에 pH 8 내지 11로 조절한 후 50 내지 60℃온도에서 40내지 120분 동안 가열함을 특징으로 하는 방법.
  4. 제1항에 있어서, 바이러스 수득물을 처음에 pH 9 내지 10로 조절한 후 55 내지 60℃온도에서 60내지 90분 동안 가열함을 특징으로 하는 방법.
  5. 제1항에 있어서, 조류의 전염성 상피종(fowl pos)바이러스를 사용하여 수행함을 특징으로 하는 방법.
  6. 제1항에 있어서, 파라믹소바이러스(paramy xovirus) 또는 레오바이러스(reovirus)를 사용하여 수행함을 특징으로 하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880013396A 1987-10-17 1988-10-14 비-특이적 면역 유도물질의 제조방법 KR0130775B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE3735277 1987-10-17
DEP3735277.6 1987-10-17
DEP3816139.7 1988-05-11
DE3816139A DE3816139A1 (de) 1987-10-17 1988-05-11 Verfahren zur herstellung von paramunitaetsinducern

Publications (2)

Publication Number Publication Date
KR890006254A true KR890006254A (ko) 1989-06-12
KR0130775B1 KR0130775B1 (ko) 1998-04-09

Family

ID=25860889

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880013396A KR0130775B1 (ko) 1987-10-17 1988-10-14 비-특이적 면역 유도물질의 제조방법

Country Status (11)

Country Link
US (1) US5094850A (ko)
EP (1) EP0312839B1 (ko)
JP (1) JPH0813269B2 (ko)
KR (1) KR0130775B1 (ko)
AU (1) AU618287B2 (ko)
CA (1) CA1338758C (ko)
DE (2) DE3816139A1 (ko)
DK (1) DK171798B1 (ko)
ES (1) ES2054759T3 (ko)
IL (1) IL88048A0 (ko)
NZ (1) NZ226569A (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2099678B1 (es) * 1995-11-03 1998-02-16 Grifols Grupo Sa Procedimiento para la inactivacion de virus en proteinas.
WO1998009660A1 (en) * 1996-09-06 1998-03-12 Epic Therapeutics, Inc. Viral inactivation of biological fluids with biomolecule activity retention
US6632647B2 (en) * 2000-07-11 2003-10-14 Bayer Aktiengesellschaft Use of strains of parapoxvirus ovis against organ fibrosis
AU2002362072A1 (en) 2001-12-07 2003-06-23 Board Of Regents The University Of Texas System Use a parapox b2l protein to modify immune responses to administered antigens
PT1951274E (pt) 2005-11-24 2009-12-14 Aicuris Gmbh & Co Kg Parapoxvírus em combinação com agentes quimioterapêuticos citotóxicos clássicos como bioquimioterapia para o tratamento de cancro
US9493744B2 (en) * 2012-06-20 2016-11-15 Genentech, Inc. Methods for viral inactivation and other adventitious agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1021133B (de) * 1956-10-24 1957-12-19 Dr Med Karl Theurer Verfahren zur Herstellung von Impfstoffen gegen Viruserkrankungen
EP0037441B1 (en) * 1980-03-10 1984-05-09 Seiji Arakawa Pharmaceutical compositions useful as cellular immunopotentiator and anti-tumor agent, process for production thereof and microorganism used therein
DE3473407D1 (en) * 1983-05-02 1988-09-22 Immuno Ag Method of inactivating pathogens
HU197517B (en) * 1984-07-30 1989-04-28 Laszlo Csatary Process for production of terapeutical composition applicable against virus infection

Also Published As

Publication number Publication date
AU2394488A (en) 1989-04-20
JPH0813269B2 (ja) 1996-02-14
AU618287B2 (en) 1991-12-19
DE3816139A1 (de) 1989-04-27
NZ226569A (en) 1991-02-26
IL88048A0 (en) 1989-06-30
EP0312839A3 (en) 1990-03-14
DK171798B1 (da) 1997-06-02
DE3881326D1 (de) 1993-07-01
CA1338758C (en) 1996-12-03
JPH02432A (ja) 1990-01-05
ES2054759T3 (es) 1994-08-16
EP0312839A2 (de) 1989-04-26
DK573888A (da) 1989-04-18
DK573888D0 (da) 1988-10-14
EP0312839B1 (de) 1993-05-26
KR0130775B1 (ko) 1998-04-09
US5094850A (en) 1992-03-10

Similar Documents

Publication Publication Date Title
NO20013701L (no) HER-2/neu-fusjonsproteiner
IT1190792B (it) Procedimento per preparare composizioni di enzimi coagulanti del sangue
DK541889A (da) Virus-modificerede tumorvacciner til immunterapi af tumormetastaser
DK190387A (da) Vaccine
DK343179A (da) Hepatitisvirus og fremgangsmaade til dyrkning deraf
KR890006254A (ko) 비-특이적 면역성 인듀서의 제조방법
ATE179614T1 (de) Herpes simplex virus vp16 impfstoffe
ATE365206T1 (de) Verfahren zur entwicklung von einem hiv impfstoff
DE3775321D1 (de) Verfahren zur kultur des virus der rhinotracheitis des truthahnes und daraus hergestelltes vakzin.
ATE136468T1 (de) Impfstoff zur behandlung von hsv
ES422966A1 (es) Un metodo para inactivar un virus.
ES330109A1 (es) Procedimiento para la preparacion de colorantes basicos acuosolubles.
IT1207208B (it) Asciugabiancheria perfezionato eprocedimento di riscaldamento relativo.
FI853562A0 (fi) Foerfarande foer framstaellning av haollbara, rikligt verkningsaemnen innehaollande kamomillextrakt.
ES2062990T3 (es) Vacunas, que contienen la proteina f del virus del sida.
FR2517967B1 (ko)
IE38423L (en) Neonatal calf diarrhea vaccine.
ATE3058T1 (de) Herpes-virus-impfstoff und seine herstellung.
SE8700466D0 (sv) Vaccines against melanoma
DE3852762D1 (de) Expression der immunoaktiven proteine von menschlichem b-lymphotropikvirus.
KR880012165A (ko) 차 추출액의 개선된 가공 방법
DK569985A (da) Vaccine indeholdende inaktiveret infektioes fuglebronkitisvirus
OA03962A (fr) Préparation d'extraits antigènes de thymocytes animaux, de sérums et de gamma-globulines antithymocytaires spécifiques d'une espèce animale.
JPS5545618A (en) Thermal treatment of fraction containing glycoprotein which accelerates differentiation and proliferation of human granulocyte
ATE177010T1 (de) Immunverstärkung von impfstoffen, besonders von impfstoffen gegen schweinepleuropneumonie

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20111028

Year of fee payment: 15

EXPY Expiration of term